Nykode Therapeutics AS (OSL:NYKD)
Norway · Delayed Price · Currency is NOK 4.805
+0.205 (4.46%)
Aug 27, 2026, 9:25 AM CET
Nykode Therapeutics AS Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | - | 8.68 | 12.9 | 7.17 | 33.96 |
Other Revenue | 0.46 | 0.45 | 0.48 | 0.42 | 1.86 | 1.8 |
| 0.46 | 0.45 | 9.16 | 13.32 | 9.03 | 35.77 | |
Revenue Growth | -94.12% | -95.05% | -31.26% | 47.56% | -74.76% | -83.42% |
Gross Profit | 0.46 | 0.45 | 9.16 | 13.32 | 9.03 | 35.77 |
Selling, General & Admin | 12.39 | 13.87 | 31.55 | 28.42 | 18.8 | 17.51 |
Other Operating Expenses | 13.6 | 13.14 | 23.69 | 40.87 | 41.57 | 28.3 |
Operating Expenses | 28.11 | 29.04 | 57.49 | 71.41 | 62.19 | 46.54 |
Operating Income | -27.65 | -28.59 | -48.33 | -58.08 | -53.16 | -10.78 |
Interest Expense | -0.24 | -0.12 | -0.19 | -0.22 | -0.24 | -0.13 |
Interest & Investment Income | 3.55 | 3.55 | 7 | 8.95 | 3.69 | 0.27 |
Currency Exchange Gain (Loss) | 7.46 | 7.46 | -4 | 5.27 | -1.24 | -0.63 |
Other Non Operating Income (Expenses) | -7.42 | - | - | - | -0.14 | 0.03 |
EBT Excluding Unusual Items | -24.29 | -17.7 | -45.51 | -44.09 | -51.09 | -11.23 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.1 | 0.12 |
Pretax Income | -24.29 | -17.7 | -45.51 | -44.09 | -50.98 | -11.12 |
Income Tax Expense | -1.34 | -5.46 | -6.69 | -8.93 | -8.24 | -1.7 |
Net Income | -22.95 | -12.24 | -38.82 | -35.15 | -42.74 | -9.41 |
Net Income to Common | -22.95 | -12.24 | -38.82 | -35.15 | -42.74 | -9.41 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 359 | 327 | 327 | 301 | 290 | 286 |
Shares Outstanding (Diluted) | 359 | 327 | 327 | 301 | 290 | 286 |
Shares Change | 10.02% | - | 8.66% | 3.58% | 1.32% | -3.31% |
EPS (Basic) | -0.06 | -0.04 | -0.12 | -0.12 | -0.15 | -0.03 |
EPS (Diluted) | -0.07 | -0.04 | -0.12 | -0.12 | -0.15 | -0.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -27.14 | -29.49 | -51.29 | -98.53 | -23.37 | 0.28 |
Free Cash Flow Per Share | -0.08 | -0.09 | -0.16 | -0.33 | -0.08 | 0.00 |
Dividend Per Share | - | - | 0.088 | - | - | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -5958.40% | -6310.82% | -527.75% | -435.95% | -588.73% | -30.13% |
Profit Margin | -4946.77% | -2701.99% | -423.90% | -263.86% | -473.40% | -26.32% |
Free Cash Flow Margin | -5850.00% | -6510.82% | -560.07% | -739.52% | -258.81% | 0.79% |
EBITDA | -26.94 | -27.86 | -47.59 | -57.45 | -52.74 | -10.69 |
EBITDA Margin | - | - | - | - | - | -29.89% |
D&A For EBITDA | 0.71 | 0.73 | 0.74 | 0.63 | 0.42 | 0.09 |
EBIT | -27.65 | -28.59 | -48.33 | -58.08 | -53.16 | -10.78 |
EBIT Margin | - | - | - | - | - | -30.13% |
Revenue as Reported | 0.46 | 0.45 | 9.16 | 13.32 | 9.03 | 35.77 |